50 results on '"Mizumoto C"'
Search Results
2. Pretransplant serum ferritin and C-reactive protein as predictive factors for early bacterial infection after allogeneic hematopoietic cell transplantation
- Author
-
Kanda, J, Mizumoto, C, Ichinohe, T, Kawabata, H, Saito, T, Yamashita, K, Kondo, T, Takakura, S, Ichiyama, S, Uchiyama, T, and Ishikawa, T
- Published
- 2011
- Full Text
- View/download PDF
3. Impaired Gastric Slow Waves Induced by Spatial Disorientation and Effect of Domperidone.
- Author
-
Kono, Toshihiko, Tokumaru, O., Mizumoto, C., Tatsuno, J., and Chen, J. D. Z.
- Subjects
DOMPERIDONE ,MOTION sickness ,SIMULATOR sickness ,PHARMACODYNAMICS ,DISEASES - Abstract
OBJECTIVES: Our aims were to investigate the dominant frequency and regularity of gastric myoelectrical activity during motion sickness induced with the advanced spatial disorientation demonstrator (ASDD) and to evaluate the effect of domperidone on gastric myoelectrical activity and gastrointestinal symptoms during motion sickness. METHODS: Thirteen healthy volunteers participated in this study. This study was executed using the ASDD, which could duplicate several spatial disorientation phenomena in a safe, controlled environment. Each subject participated in two sessions and received oral administration of 10 mg domperidone before the study in one of the sessions. In each session, three 15-min EGG recordings were made before, during, and after rotation, The symptoms were scored by Graybiel's scale of motion sickness before and after rotation, All EGG data were subjected to computerized spectral analysis to obtain the percentage of normal 2-4 cycles/min (cpm) slow waves, percentage of tachygastria, EGG dominant frequency and power, and instability coefficient of the dominant frequency. RESULTS: We have found that the percentage of normal gastric slow wave was decreased (control session: 86.2 ± 4.0% vs 70.0 ± 5.4%, p < 0.01; domperidone session: 82.7 ± 4.6% vs 69.8 ± 5.6%, p < 0.03) and the percentage of tachygastria was increased (control session: 8.7 ± 3.2% vs 17.8 ± 5.6%, p < 0.01; domperidone session: 9.2 ± 3.3% vs 18.1 ± 3.5%, p < 0.01) after rotation in both sessions. The minute-by-minute variation of the gastric slow wave frequency was significantly increased during rotation in both sessions (control: 0.74 ± 0.16 vs 1.35 ± 0.19, p < 0.01; domperidone: 0.90 ± 0.20 vs 1.47 ± 0.17, p < 0.01). Domperidone did not prevent dysrhythmia or the symptoms of motion sickness. CONCLUSIONS: The percentage of normal gastric... [ABSTRACT FROM AUTHOR]
- Published
- 1999
- Full Text
- View/download PDF
4. Influence of glycogen on water proton relaxation times.
- Author
-
Gore, J. C., Brown, M. S., Mizumoto, C. T., and Armitage, I. M.
- Published
- 1986
- Full Text
- View/download PDF
5. Population Pharmacokinetic Modeling of Posaconazole in Japanese Patients Receiving Fungal Prophylaxis.
- Author
-
Sugimoto M, Yonezawa A, Kanda J, Itohara K, Hira D, Yamagiwa T, Taniguchi R, Hanyu Y, Watanabe M, Arai Y, Mizumoto C, Kitawaki T, Kondo T, Yamashita K, Takaori-Kondo A, and Terada T
- Subjects
- Humans, Male, Female, Middle Aged, Retrospective Studies, Adult, Aged, Japan, Young Adult, Asian People, Administration, Oral, East Asian People, Triazoles pharmacokinetics, Triazoles therapeutic use, Antifungal Agents pharmacokinetics, Antifungal Agents therapeutic use, Mycoses prevention & control, Hematopoietic Stem Cell Transplantation, Models, Biological
- Abstract
Background: Posaconazole is a vital drug to treat and prevent invasive fungal infections. Several factors, such as sex, body weight, total serum proteins, dietary intake, and severe mucositis, affect posaconazole pharmacokinetics (PKs). However, the relevance of other factors that affect the PKs of posaconazole in hematopoietic stem cell transplantation (HSCT) is unknown. This study explored factors influencing the PKs of posaconazole in HSCT recipients and nontransplant patients with hematological diseases., Methods: The authors conducted a single-institution, retrospective study. Forty-two Japanese inpatients receiving oral posaconazole tablets as prophylaxis for fungal infections were enrolled in this study. A one-compartment model with first-order absorption was used as the structural pharmacokinetic model. A population PK (PopPK) analysis was performed using a nonlinear mixed-effects modeling program, using a first-order conditional estimation method with interactions. Perl-speaks-NONMEM and R were used to evaluate the goodness of fit and visualize the output., Results: In 29% of the enrolled patients, the serum concentration of posaconazole was <0.5 mcg/mL, considered the effective range. PopPK analysis revealed that the patient had undergone HSCT within 1 year, diarrhea occurred more than 5 times a day, and aspartate aminotransferase were covariates that influenced apparent clearance (CL/F). The CL/F of posaconazole was 1.43-fold higher after HSCT and 1.26-fold higher during diarrhea., Conclusions: PopPK analysis revealed that HSCT, diarrhea, and aspartate aminotransferase were factors associated with the CL/F of posaconazole. The trough concentration of posaconazole may be below the therapeutic range in a few patients with diarrhea and/or after HSCT. As invasive fungal infections in patients with hematologic diseases can be life-threatening, therapeutic drug monitoring of posaconazole is strongly recommended, and patients should be carefully monitored., Competing Interests: The authors declare no conflict of interest., (Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
6. Utilizing red blood cell distribution width (RDW) as a reliable biomarker to predict treatment effects after chimeric antigen receptor T cell therapy.
- Author
-
Nakamura N, Jo T, Arai Y, Kitawaki T, Nishikori M, Mizumoto C, Kanda J, Yamashita K, Nagao M, and Takaori-Kondo A
- Subjects
- Humans, Male, Female, Middle Aged, Adult, Aged, Prognosis, Treatment Outcome, Biomarkers blood, Receptors, Chimeric Antigen, Cohort Studies, Young Adult, Leukapheresis, Erythrocyte Indices, Immunotherapy, Adoptive methods, Lymphoma, Large B-Cell, Diffuse therapy, Lymphoma, Large B-Cell, Diffuse blood
- Abstract
Chimeric antigen receptor T cell (CAR-T) therapy is an effective treatment for B cell malignancies. A certain fraction of patients, however, experience post-CAR-T relapse, and due to the difficulty of precise relapse prediction, biomarkers that can predict the strength and duration of CAR-T efficacy are needed before CAR-T infusion. Therefore, we performed a single-center cohort study including 91 diffuse large B cell lymphoma (DLBCL) patients treated with CAR-T in order to identify such a new prognostic biomarker. After confirming that each of the already reported prognostic parameters (disease status at leukapheresis, primary refractoriness, number of treatment lines, CD3
+ cell counts at leukapheresis) has only limited predictive performance, we established a new composite parameter by integrating these four variables, and found that it predicts progression-free survival (PFS) after CAR-T infusion with statistical significance. Moreover, after comprehensive correlation analyses of this new composite parameter with all individual laboratory variables, we determined that the standard deviation of red blood cell distribution width (RDW-SD) at leukapheresis shows significant correlation with the composite parameter and may be a prognostic biomarker (R2 = 0.76, p = 0.02). Validation analysis indicated that a higher RDW-SD is significantly associated with poorer PFS after CAR-T cell therapy (HR, 3.46, P = 0.03). Thus, this study suggests that a single parameter, RDW-SD at leukapheresis, is a novel, useful biomarker that can be obtained early to predict therapeutic effects of CAR-T cell therapy. Post-CAR-T maintenance or re-induction therapies should be adopted for higher risk patients, who may relapse after CAR-T therapy., (© 2024. The Author(s).)- Published
- 2024
- Full Text
- View/download PDF
7. Clinical Impact of Cytokine Release Syndrome on Prolonged Hematotoxicity after Chimeric Antigen Receptor T Cell Therapy: KyoTox A-Score, a Novel Prediction Model.
- Author
-
Nakamura N, Jo T, Arai Y, Kitawaki T, Nishikori M, Mizumoto C, Kanda J, Yamashita K, Nagao M, and Takaori-Kondo A
- Subjects
- Humans, Cytokine Release Syndrome etiology, Retrospective Studies, Cell- and Tissue-Based Therapy, Receptors, Chimeric Antigen, Cytopenia, Thrombocytopenia, Neutropenia, Anemia
- Abstract
Prolonged hematotoxicity is the most common long-term adverse event in chimeric antigen receptor T cell therapy (CAR-T). To evaluate the impact on prolonged cytopenia of inflammatory status after CAR T infusion, we performed a single-center retrospective study and analyzed patients with B cell lymphomas after CAR-T. Among 90 patients analyzed at 90 days after infusion, the cumulative incidence was 57.5% for prolonged neutropenia, 36.7% for anemia, and 49.8% for thrombocytopenia. Patients who experienced cytokine release syndrome (CRS) had significantly higher incidence and longer duration of prolonged cytopenia. In addition, we found that among patients with grade 1 CRS, those with a longer duration of CRS-related symptoms (>5 days; grade 1b in modified CRS grading [m-CRS]) had a significantly higher incidence and longer duration of prolonged cytopenia than those whose CRS-related symptoms resolved within 5 days (grade 1a m-CRS). Multivariate analysis revealed that a higher m-CRS grade (grade 1b or 2; hazard ratio [HR], 2.42), higher peak CRP (≥10 mg/dL; HR, 1.66), longer duration of elevated CRP (≥10 days; HR, 1.83), and a decrease in serum inorganic phosphorus concentration (≥30% from baseline; HR, 1.95) were associated with significantly higher cumulative incidence of prolonged neutropenia, as well as anemia and thrombocytopenia. Using these factors, we developed a new predictive scoring model for prolonged hematotoxicity, the KyoTox a-score, which can successfully stratify the incidence and duration of cytopenia independent of the existing model, CAR-HEMATOTOX, which is based on laboratory data at lymphodepletion. Thus, this newly developed post-CAR-T inflammation-dependent score is accurate and useful for predicting prolonged hematotoxicity., (Copyright © 2024 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
8. KyoTox-e score; prediction of post-CAR-T prolonged thrombocytopenia using peripheral blood data before apheresis.
- Author
-
Jo T, Arai Y, Kitawaki T, Nakamura N, Nishikori M, Mizumoto C, Kanda J, Yamashita K, Nagao M, and Takaori-Kondo A
- Subjects
- Humans, Immunotherapy, Adoptive, Receptors, Chimeric Antigen, Blood Component Removal, Thrombocytopenia therapy, Anemia
- Published
- 2024
- Full Text
- View/download PDF
9. Successful treatment of lung cancer coexisting with B‑cell lymphoma with pembrolizumab following rituximab‑included chemotherapy: A case report.
- Author
-
Natori D, Ozasa H, Shima Y, Mizumoto C, Suminaga K, Nomizo T, Ajimizu H, Yoshida H, and Hirai T
- Abstract
The combined occurrence of lung cancer and B-cell lymphoma, such as mucosa-associated lymphoid tissue (MALT) lymphoma, is rare. The efficacy and safety of immune checkpoint inhibitors (ICIs) remain unknown in this population of patients, and the occurrence of ICI-induced exacerbation of lymphoma is concerning. The present study describes a case of successful treatment with pembrolizumab following rituximab-containing chemotherapy for lung cancer complicated by MALT lymphoma. The patient was a 69-year-old woman diagnosed with MALT lymphoma based on a biopsy of stomach ulcerative lesions, and advanced lung cancer based on a biopsy of a lymph node in the left pulmonary hilum. Complete remission was achieved after one cycle of rituximab and bendamustine therapy for MALT lymphoma. Pembrolizumab monotherapy was subsequently initiated, resulting in a good response for lung cancer without recurrence or exacerbation of the lymphoma. In conclusion, the present study suggested that pembrolizumab, following rituximab-containing therapy, could be a treatment option for patients with lung cancer coexisting with MALT lymphoma., Competing Interests: The authors declare that they have no competing interests., (Copyright: © 2024 Natori et al.)
- Published
- 2024
- Full Text
- View/download PDF
10. Methotrexate‑related other iatrogenic immunodeficiency‑associated lymphoproliferative disorder in the CNS and medication‑related osteonecrosis of the jaw occurring simultaneously: A case report.
- Author
-
Kato T, Mizumoto C, Inoue F, Watanabe T, Yamanaka S, Fukuhara S, and Nakao K
- Abstract
Methotrexate-related other iatrogenic immunodeficiency-associated lymphoproliferative disorder (MTX-OIIA-LPD) is prone to extranodal involvement but rarely involves the central nervous system (CNS). The present study reports a case of MTX-OIIA-LPD of the CNS discovered during medication-related osteonecrosis of the jaw (MRONJ) treatment in a 76-year-old woman with rheumatoid arthritis (RA). The chief complaint of the patient was bone exposure and pain in the right mandibular molar. The patient had been receiving MTX for RA and alendronate sodium hydrate for osteoporosis, followed by denosumab. Treatment was initiated based on a diagnosis of MRONJ. However, the patient experienced lightheadedness and floating dizziness afterwards. Examinations revealed scattered neoplastic lesions in the brain. The histopathological diagnosis was diffuse large B-cell lymphoma. A systemic search also revealed adrenal involvement. Since the patient was taking MTX, a diagnosis of MTX-OIIA-LPD was made and MTX was discontinued. Chemotherapeutic agents were administered since the central lesions became symptomatic. The MTX-OIIA-LPD lesions in the brain and adrenal glands completely resolved 8 months after onset. The physical condition of the patient improved, and the bone-exposed areas became epithelialized. Reports on MTX-LPD in the oral and maxillofacial region are few, which may delay its diagnosis. Therefore, biopsy of oral lesions in patients with MRONJ who are taking MTX and collaboration with related diagnostic departments, such as rheumatology and hematology, must be done to initiate the diagnosis and treatment of extraoral MTX-LPD., Competing Interests: The authors declare that they have no competing interests., (Copyright: © Kato et al.)
- Published
- 2023
- Full Text
- View/download PDF
11. Impact of Antimicrobial Drug-Drug Interactions on Acute Kidney Injury after Allogeneic Hematopoietic Cell Transplantation.
- Author
-
Wada F, Arai Y, Jo T, Mizumoto C, Kanda J, Kitawaki T, Nishikori M, Yamashita K, and Takaori-Kondo A
- Abstract
Acute kidney injury (AKI) is one of the major complications after allogeneic hematopoietic stem cell transplantation (allo-HSCT). The use of multiple antimicrobials is one of the major causes of post-transplantation AKI, owing to the potential nephrotoxicity of each agent and of drug-drug interactions (DDIs). No satisfactory reports on DDIs the field of allo-HSCT have been published. We performed a retrospective analysis to compare the incidence of AKI within 100 days post-transplantation. A total of 465 allo-HSCTs in 416 patients were analyzed, and the cumulative incidence of AKI was 40.0%. AKI was associated with significantly reduced overall survival (hazard ratio [HR], 2.66; 95% confidence interval [CI] 1.95 to 3.55; P < .01) and increased transplantation-related mortality (HR, 4.77, 95% CI, 2.90 to 7.88; P < .01). A higher incidence of AKI was significantly associated with the use of ciprofloxacin, cefepime, tazobactam/piperacillin, meropenem, vancomycin, liposomal amphotericin B, ganciclovir, and foscarnet. Among these drugs, combinations of vancomycin plus tazobactam/piperacillin (HR, 2.23; P = .09 for interaction), ganciclovir plus cefepime (HR, 5.93; P = .04), and ganciclovir plus meropenem (HR, 2.63; P = .12) synergistically increased the risk of AKI, whereas combinations involving teicoplanin did not. This is the first report dealing with DDIs after allo-HSCT, indicating that such combinations should be avoided to preserve renal function and reduce AKI-related morbidity and mortality., (Copyright © 2023 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
12. Risk analysis of fluctuating hypercalcemia after leukapheresis in cellular therapy.
- Author
-
Jo T, Arai Y, Kitawaki T, Nishikori M, Mizumoto C, Kanda J, Yamashita K, Nagao M, and Takaori-Kondo A
- Subjects
- Humans, Calcium, Leukapheresis, Cell- and Tissue-Based Therapy, Body Weight, Risk Assessment, Hypercalcemia therapy, Hypocalcemia etiology, Hypocalcemia therapy
- Abstract
Optimized management of citrate-induced hypocalcemia is required to provide safe leukapheresis. We prospectively analyzed subjects who underwent leukapheresis for cytotherapy, and evaluated serum ionized (iCa) concentrations before, at the end of, and 1 h after leukapheresis. During leukapheresis, calcium gluconate solution was continuously supplemented intravenously with hourly measurement of iCa. 76 patients including 49 lymphapheresis for chimeric antigen receptor T-cell therapy and 27 stem cell collections were enrolled. Median processing blood volume was 10 L (range, 6-15 L). Fluctuating hypercalcemia, in which the iCa concentration rose above its upper limit 1 h after leukapheresis, was observed in 58 subjects (76.3%). Multivariate analysis revealed that higher ratios of processing blood volume to body weight, more rapid calcium supplementation, and lower iCa concentration at the end of leukapheresis significantly increased elevation of serum iCa concentration by 1 h after leukapheresis. Based on multivariate analyses, we developed a formula and a diagram that accurately estimates serum iCa concentration 1 h post-leukapheresis. This suggests optimal targets for iCa concentration and calcium supplementation rates. In cases with high ratios of processing blood volume to body weight, slowing the rate of blood processing, rather than increasing calcium supplementation should safely alleviate hypocalcemia during leukapheresis without inducing hypercalcemia thereafter., (© 2023. Springer Nature Limited.)
- Published
- 2023
- Full Text
- View/download PDF
13. Successful treatment with cyclosporine of pure red cell aplasia induced by obinutuzumab bendamustine therapy.
- Author
-
Shimazu Y, Mizumoto C, Chonabayashi K, Hanyu Y, Kanda J, and Takaori-Kondo A
- Subjects
- Humans, Bendamustine Hydrochloride adverse effects, Antibodies, Monoclonal, Humanized adverse effects, Immunosuppressive Agents adverse effects, Cyclosporine adverse effects, Red-Cell Aplasia, Pure chemically induced, Red-Cell Aplasia, Pure drug therapy
- Published
- 2023
- Full Text
- View/download PDF
14. An adult case of refractory autoimmune neutropenia after liver transplantation.
- Author
-
Sun H, Wada F, Kanda J, Mizumoto C, Ito T, Masano Y, Uchida Y, Hatano E, Yurugi K, Hishida R, Yamashita K, and Takaori-Kondo A
- Subjects
- Male, Humans, Adult, Middle Aged, Immunoglobulins, Intravenous, Tacrolimus adverse effects, Living Donors, Granulocyte Colony-Stimulating Factor adverse effects, Liver Transplantation adverse effects, Neutropenia etiology, Neutropenia chemically induced, Myelodysplastic Syndromes
- Abstract
Autoimmune neutropenia (AIN) is an exceptionally rare condition that occurs after liver transplantation. Here, we report an adult case of refractory AIN 3.5 years after liver transplantation. A 59-year-old man who underwent brain-dead donor liver transplantation in August 2018 developed rapid neutropenia (0.07 × 10
9 /L) in December 2021. The patient was diagnosed with AIN based on positivity for anti-human neutrophil antigen-1a antibody. There was no response to granulocyte colony-stimulating factor (G-CSF), prednisolone, or rituximab, and intravenous immunoglobulin (IVIg) therapy induced only a temporary recovery in neutrophil count. The patient continued to have a low neutrophil count for several months. However, the response to IVIg and G-CSF improved after the post-transplant immunosuppressant was changed from tacrolimus to cyclosporine. Post-transplant AIN has many unknown aspects. Tacrolimus-induced immunomodulation and graft-associated alloimmunity may be involved in its pathogenesis. Further studies are needed to elucidate the underlying mechanisms and explore new treatment options., (© 2023. Japanese Society of Hematology.)- Published
- 2023
- Full Text
- View/download PDF
15. Successful azacitidine therapy for myelodysplastic syndrome associated with VEXAS syndrome.
- Author
-
Kataoka A, Mizumoto C, Kanda J, Iwasaki M, Sakurada M, Oka T, Fujimoto M, Yamamoto Y, Yamashita K, Nannya Y, Ogawa S, and Takaori-Kondo A
- Subjects
- Aged, Humans, Male, Exanthema, Fever, Inflammation complications, Mutation, Enzyme Inhibitors therapeutic use, Azacitidine therapeutic use, Myelodysplastic Syndromes complications, Myelodysplastic Syndromes drug therapy, Myelodysplastic Syndromes genetics
- Abstract
VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome is caused by UBA1 somatic mutations and is characterized by late-onset systemic autoimmune inflammation and blood abnormalities such as cytopenia, vacuolation of myeloid/erythroblastic cells, and myelodysplastic syndrome (MDS). It is often resistant to immunosuppressive therapy, and no treatment strategy has been established. A 65-year-old man presented with palpable erythema, fever, macrocytic anemia, and arthralgia. He was subsequently diagnosed with MDS complicated by Sweet's disease. Treatment with azacitidine was initiated due to suspected skin invasion by MDS cells and resistance of the skin rash to steroid therapy. Next-generation sequencing of bone marrow samples prior to treatment initiation revealed the presence of UBA1 p.M41L (VAF 0.38) and DNMT3A p.L605fs mutations (VAF 0.184). Based on the findings of systemic inflammation, a diagnosis of VEXAS syndrome was made. The fever and skin rash improved with azacitidine therapy. In conclusion, somatic mutations in UBA1 should be explored in patients with MDS exhibiting systemic autoimmune inflammation. Furthermore, azacitidine may be a good treatment option for systemic autoinflammation in MDS associated with VEXAS syndrome., (© 2023. Japanese Society of Hematology.)
- Published
- 2023
- Full Text
- View/download PDF
16. Significance of Omitting Day 11 Mini-Dose Methotrexate for GVHD Prophylaxis After Unrelated Bone Marrow Transplantation.
- Author
-
Nakamura N, Wada F, Kondo T, Aoki K, Arai Y, Mizumoto C, Kanda J, Kitawaki T, Yamashita K, and Takaori-Kondo A
- Subjects
- Humans, Bone Marrow Transplantation adverse effects, Retrospective Studies, Transplantation, Homologous adverse effects, Methotrexate therapeutic use, Graft vs Host Disease etiology, Graft vs Host Disease prevention & control
- Abstract
The combination of calcineurin inhibitors and short-term methotrexate has been used as a standard graft-versus-host-disease (GVHD) prophylaxis in allogeneic hematopoietic stem cell transplantation. Mini-dose methotrexate (mini-MTX), consisting of 5 mg/m
2 /d on days 1, 3, 6, and 11, is occasionally selected as an alternative considering toxicity. The significance of day 11 administration remains unclear. We performed a retrospective study of 135 cases of unrelated bone marrow transplantation at our institute between 2006 and 2019 and compared the outcomes between day 11 MTX dose omitted (n = 72) and full-doses of mini-MTX (n = 63). In total cohort, the 4-year overall survival (OS) was 58.7 %, and the omitted group showed poor GVHD/relapse-free-survival (P = .01) with comparable OS (P = .11) and relapse-free survival (P = .11). Human leukocyte antigen (HLA) mismatch is a major risk factor for severe GVHD. We analyzed the impact of omitting day 11 MTX in 2 cohorts from HLA matched or mismatched donors. In both cohorts, the omitted group had a higher risk of severe acute and chronic GVHD. In conclusion, the omission of day 11 MTX was associated with a higher risk of severe GVHD. Therefore the omission of the day 11 dose is not recommended., (Copyright © 2022 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights reserved.)- Published
- 2023
- Full Text
- View/download PDF
17. Decreased serum phosphate levels are a useful biomarker to predict occurrence and severity of cytokine release syndrome in chimeric antigen receptor T-cell therapy.
- Author
-
Nakamura N, Arai Y, Kitawaki T, Jo T, Mizumoto C, Kanda J, Nishikori M, Yamashita K, and Takaori-Kondo A
- Subjects
- Humans, Cytokine Release Syndrome etiology, Immunotherapy, Adoptive adverse effects, Biomarkers, Cell- and Tissue-Based Therapy, Phosphates, Receptors, Antigen, T-Cell genetics, Receptors, Chimeric Antigen
- Published
- 2023
- Full Text
- View/download PDF
18. T-cell counts in peripheral blood at leukapheresis predict responses to subsequent CAR-T cell therapy.
- Author
-
Wada F, Jo T, Arai Y, Kitawaki T, Mizumoto C, Kanda J, Nishikori M, Yamashita K, Nagao M, and Takaori-Kondo A
- Subjects
- Humans, Leukapheresis, T-Lymphocytes, Neoplasm Recurrence, Local drug therapy, Receptors, Antigen, T-Cell, Cell- and Tissue-Based Therapy, Cell Count, Antigens, CD19, Receptors, Chimeric Antigen, Lymphoma, Large B-Cell, Diffuse pathology
- Abstract
Prediction of responses to chimeric antigen receptor (CAR)-T cell therapies is essential to maximize their therapeutic efficacy for diffuse large B-cell lymphoma (DLBCL). While several tumor-intrinsic risk factors of resistance and/or early relapse have been identified, clinically useful markers that determine potential activity of CAR-T cells have not been fully investigated. T-cell property at the time of leukapheresis may serve as such a marker. Therefore, we evaluated the clinical impact of CD3
+ cell count in peripheral blood at leukapheresis on clinical outcomes of CAR-T cell therapy. In total, 44 patients with relapsed or refractory (r/r) DLBCL who received tisagenlecleucel at Kyoto University Hospital were included. According to CD3+ cell counts, patients were categorized into CD3LOW and CD3HIGH groups with a threshold of 553/μL, based on receiver operating characteristic curve analysis. 1-year progression-free survival was significantly higher in the CD3HIGH group than the CD3LOW group (68.3% vs. 17.3%; adjusted hazard ratio [aHR], 0.37; p = 0.042). Overall survival was also superior in the CD3HIGH group (aHR, 0.24; p = 0.043). Moreover, higher CD3+ cell counts at leukapheresis were associated with significantly higher lymphocyte counts in peripheral blood at day 7 after CAR-T cell infusion (median 860 vs. 420/μL, P = 0.021), suggesting more extensive expansion of infused CAR-T cells in vivo. In conclusion, we demonstrated that the CD3+ cell count at leukapheresis predicts both expansion of CAR-T cells after infusion and outcomes of CAR-T cell therapy, and are useful for building comprehensive therapeutic strategies at the time of leukapheresis., (© 2022. The Author(s).)- Published
- 2022
- Full Text
- View/download PDF
19. Relative hypercoagulation induced by suppressed fibrinolysis after tisagenlecleucel infusion in malignant lymphoma.
- Author
-
Yamasaki-Morita M, Arai Y, Ishihara T, Onishi T, Shimo H, Nakanishi K, Nishiyama Y, Jo T, Hiramatsu H, Mitsuyoshi T, Mizumoto C, Kanda J, Nishikori M, Kitawaki T, Nogami K, Takaori-Kondo A, Nagao M, and Adachi S
- Subjects
- Adult, Antigens, CD19, Fibrinolysis, Humans, Lymphoma, Large B-Cell, Diffuse drug therapy, Lymphoma, Non-Hodgkin drug therapy, Plasminogen Activator Inhibitor 1, Prospective Studies, Receptors, Antigen, T-Cell therapeutic use, Blood Coagulation Disorders drug therapy, Blood Coagulation Disorders etiology, Receptors, Chimeric Antigen therapeutic use, Thrombophilia
- Abstract
Anti-CD19 chimeric antigen receptor T (CAR-T) cell therapy has facilitated progress in treatment of refractory/relapsed diffuse large B-cell lymphoma (DLBCL). A well-known adverse event after CAR-T therapy is cytokine release syndrome(CRS). However, the etiology and pathophysiology of CRS-related coagulopathy remain unknown. Therefore, we conducted a prospective cohort study to comprehensively analyze coagulation/ fibrinolysis parameters present in peripheral blood of adult DLBCL patients treated with tisagenlecleucel in a single institution. Samples were collected from 25 patients at 3 time points: before lymphocyte-depletion chemotherapy and on days 3 and 13 after CAR-T infusion. After infusion, all patients except 1 experienced CRS, and 13 required the administration of tocilizumab. A significant elevation in the plasma level of total plasminogen activator inhibitor 1 (PAI-1), which promotes the initial step of coagulopathy (mean, 22.5 ng/mL before lymphocyte-depletion and 41.0 on day 3, P = .02), was observed at the onset of CRS. Moreover, this suppressed fibrinolysis-induced relatively hypercoagulable state was gradually resolved after CRS remission with normalization of total PAI-1 to preinfusion levels without any organ damage (mean values of soluble fibrin: 3.16 µg/mL at baseline, 8.04 on day 3, and 9.16 on day 13, P < .01; and mean PAI-1: 25.1 ng/mL on day 13). In conclusion, a hypofibrinolytic and relatively hypercoagulable state concomitant with significant total PAI-1 elevation was observed at the onset of CRS even in DLBCL patients with mild CRS. Our results will facilitate understanding of CRS-related coagulopathy, and they emphasize the importance of monitoring sequential coagulation/fibrinolysis parameters during CAR-T therapy., (© 2022 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
20. Addition and drug monitoring of mycophenolate mofetil for GVHD prophylaxis in unrelated bone marrow transplantation.
- Author
-
Wada F, Kondo T, Yamamoto R, Yamagiwa T, Arai Y, Mizumoto C, Kanda J, Kitawaki T, Yamashita K, and Takaori-Kondo A
- Subjects
- Bone Marrow Transplantation, Cyclosporine therapeutic use, Drug Monitoring, Humans, Immunosuppressive Agents therapeutic use, Mycophenolic Acid therapeutic use, Graft vs Host Disease drug therapy, Graft vs Host Disease prevention & control, Hematopoietic Stem Cell Transplantation
- Published
- 2022
- Full Text
- View/download PDF
21. Successful allogeneic bone marrow transplantation in a case of variant acute promyelocytic leukemia with ZBTB16-RARA.
- Author
-
Morimoto S, Kondo T, Taya T, Matsuo H, Teramoto Y, Mizumoto C, Kanda J, Yamashita K, and Takaori-Kondo A
- Subjects
- Bone Marrow Transplantation, Humans, Oncogene Proteins, Fusion genetics, Promyelocytic Leukemia Zinc Finger Protein, Retinoic Acid Receptor alpha genetics, Translocation, Genetic, Hematopoietic Stem Cell Transplantation, Leukemia, Promyelocytic, Acute genetics, Leukemia, Promyelocytic, Acute therapy
- Published
- 2022
- Full Text
- View/download PDF
22. Low-dose dasatinib in older patients with chronic myeloid leukaemia in chronic phase (DAVLEC): a single-arm, multicentre, phase 2 trial.
- Author
-
Murai K, Ureshino H, Kumagai T, Tanaka H, Nishiwaki K, Wakita S, Inokuchi K, Fukushima T, Yoshida C, Uoshima N, Kiguchi T, Mita M, Aoki J, Kimura S, Karimata K, Usuki K, Shimono J, Chinen Y, Kuroda J, Matsuda Y, Nakao K, Ono T, Fujimaki K, Shibayama H, Mizumoto C, Takeoka T, Io K, Kondo T, Miura M, Minami Y, Ikezoe T, Imagawa J, Takamori A, Kawaguchi A, Sakamoto J, and Kimura S
- Subjects
- Aged, Dasatinib adverse effects, Drug Administration Schedule, Female, Fusion Proteins, bcr-abl, Humans, Male, Treatment Outcome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive drug therapy
- Abstract
Background: BCR-ABL1 tyrosine kinase inhibitors (TKIs) are commonly initiated in older patients with chronic myeloid leukaemia in the chronic phase at standard doses. However, because of their safety profile in this population, appropriate therapy has not been established. We aimed to investigate whether a lower than standard dose of dasatinib was an appropriate therapy for older patients with chronic myeloid leukaemia in the chronic phase., Methods: DAsatinib, Very Low-dose, for Elderly CML-CP patients (DAVLEC) was a multicentre, single-arm, phase 2 trial done in 25 Japanese hospitals. We enrolled patients older than 70 years with newly diagnosed chronic myeloid leukaemia in the chronic phase, ECOG performance status 0-2, and no previous treatment for CML other than hydroxyurea within 4 weeks. Second-generation TKI dasatinib was given orally at a starting dose of 20% of the standard dose (20 mg/day). If the treatment was assessed as optimal response at 3 months, 6 months, and 9 months and adverse events were grade 2 or better (according to the NCI Common Toxicity Criteria v 4.0), the same dose was continued. If response was suboptimal and adverse events were grade 2 or better, the dose was increased by 20 mg/day. Once a dose reduction had been made because of a grade 3 or worse adverse event, there were no further dose increases. Treatment was discontinued if assessed as failure (disease progression to the accelerated phase or acute phase). The primary endpoint was the achievement of major molecular response at 12 months, assessed using a per-protocol analysis. This trial is registered at with the UMIN clinical trial registry, UMIN000024548, and has completed its planned observation period., Findings: Between Nov 1, 2016, and Oct 30, 2019, 52 patients received first-line dasatinib therapy at 20 mg/day. The median age at diagnosis was 77·5 years (73·5-83·0). 35 (67%) patients were male and 17 (33%) were female. 31 (60%) of 52 patients reached major molecular response at 12 months (one-sided 95% CI 48-71), with a median follow-up of 366 days (IQR 353-372). Grade 3-4 adverse events were reported in 12 (23%) patients. Neutropenia was the most frequent grade 3-4 adverse event, occurring in three (6%) patients. No treatment-related deaths were observed., Interpretation: Low-dose dasatinib at 20mg/day is worthy of consideration as a starting dose for older patients with newly diagnosed chronic myeloid leukaemia in the chronic phase. However, this dose needs to be further studied in a larger cohort and with a more ethnically diverse population., Funding: Bristol-Myers Squibb., Competing Interests: Declaration of interests KM has received honoraria from Bristol-Myers Squibb, Novartis, Pfizer, Celgene, Eisai, Sanofi, Janssen, and Otsuka Pharmaceuticals. TKu received honoraria from Bristol-Myers Squibb, Novartis, Pfizer, and Otsuka Pharmaceuticals. HT received honoraria from Bristol-Myers Squibb, Novartis, Pfizer, and Otsuka Pharmaceuticals. KN received grants from Kyowa-Kirin, and honoraria from Alexion. CY received honoraria from Bristol-Myers Squibb, Novartis KK, Pfizer Japan, Otsuka Pharmaceutical, AbbVie GK, Janssen Pharmaceutical KK, Nippon Shinyaku, and Chugai Pharmaceutical. NU received honoraria from Eisai and Janssen Pharmaceutical. KU received grants from Astellas Pharma, AbbVie, Apellis, SymBio, Daiichi-Sankyo, Novartis, Janssen, Otsuka, Astellas Amgen Biopharma, Takeda, Nippon-Shinyaku, Bristol-Myers Squibb, Amgen, Alexion, Incyte, Ono, Kyowa-Kirin, Celgene, Sumitomo-Dainippon, Chugai, Pfizer, Mundi, Yakult, MSD, Gilead, and Nippon-Boehringer-Ingelheim and honoraria from Novartis, Bristol-Myers-Squibb, Sanofi, Pfizer, Abbvie, Takeda, Ono, Kyowa-Kirin, Astellas, Alexion, Eisai, MSD, Otsuka, Celgene, Daiichi-Sankyo, Nippon-Shinyaku, PharmaEssentia, Yakult, SymBio, Alexion, and Chugai. JK received grants from Bristol-Myers Squibb, Sysmex, Celgene, Ono Pharmaceutical, Otsuka Pharmaceutical, Sanofi, Kyowa Kirin, Sanofi, Chugai Pharmaceutical, Eisai, Dainippon Sumitomo Pharma, Nippon Shinyaku, Takeda, Shionogi, Asahi Kasei, Daiichi Sankyo, MSD, Taiho Pharmaceutical, and Abbvie; has received honoraria from Bristol–Myers Squibb, Janssen Pharmaceutical KK, Celgene Corporation, Ono Pharmaceutical, Takeda, Sanofi, Kyowa Kirin, Chugai Pharmaceutical, Eisai, Astellas Pharma, Nippon Shinyaku, Dainippon Sumitomo Pharma, Symbio, Daiichi Sankyo, Fujimoto Pharmaceutical, Abbvie, and Otsuka Pharmaceutical; and consulting fees from Janssen Pharmaceutical KK, Bristol-Myers Squibb, Sanofi, and Abbvie. TO received grants from Celgene, Kyowa Hakko Kirin, Chugai Pharmaceutical, TAIHO Phamaceutical; and honoraria from Celgene, Kyowa Hakko Kirin, Chugai Pharmaceutical, Novartis, Bristol-Myers Squibb, Pfizer, Otsuka Pharmaceutical, ONO Pharmaceutical, Takeda Pharmaceutical, Astellas Pharma, Eisai Pharmaceuticals, Janssen Pharm, Daiichi Sankyo, and Mundipharma. KF received honoraria from Bristol-Myers Squibb, Novartis, Pfizer, and Otsuka Pharmaceuticals. HS received honoraria from Takeda, Ono, Novartis, Janssen, Chugai, Eizai, Nippon Shinyaku, Sanofi, AstraZeneca, Bristol-Myers Squibb, Otsuka, Mundi Pharma and Kyowa Kirin; and research funding from Janssen, Ono, Celgene, Novartis, Sanofi, AstraZeneca, AbbVie, and Chugai. TKo received honoraria from Bristol-Myers Squibb, Novartis, Pfizer, Otsuka Pharmaceuticals, and Abbvie; and has served in an advisory role for Astellas Pharma and Otsuka Pharmaceutical. YMi received honoraria from Bristol-Myers Squibb, Novartis, Pfizer, and Astellas; and research funding from Ono and CMIC Holdings. ShK has received honoraria from Bristol-Myers Squibb, Novartis, Pfizer, and Otsuka Pharmaceuticals; and research funding from Bristol-Myers Squibb, Pfizer, Otsuka Pharmaceuticals, and Ohara Pharmaceuticals. All other authors declare no competing interests, (Copyright © 2021 Elsevier Ltd. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
23. Mycobacterium shigaense sp. nov., a slow-growing, scotochromogenic species, is a member of the Mycobacterium simiae complex.
- Author
-
Fukano H, Yoshida M, Kazumi Y, Fujiwara N, Katayama K, Ogura Y, Hayashi T, Miyamoto Y, Fujimoto N, Hongsheng W, Mizumoto C, Koizumi Y, Maeda H, Hiranuma O, Mitarai S, Ishii N, and Hoshino Y
- Subjects
- Bacterial Typing Techniques, Base Composition, DNA, Bacterial genetics, Fatty Acids chemistry, Humans, Japan, Mycobacterium genetics, Mycobacterium isolation & purification, Mycolic Acids chemistry, Nontuberculous Mycobacteria classification, Nontuberculous Mycobacteria genetics, Nontuberculous Mycobacteria isolation & purification, Phospholipids chemistry, Pigmentation, RNA, Ribosomal, 16S genetics, Sequence Analysis, DNA, Mycobacterium classification, Mycobacterium Infections microbiology, Phylogeny, Skin Diseases, Bacterial microbiology
- Abstract
Among non-tuberculous mycobacteria (NTM), the Mycobacterium simiae complex is one of the largest groups, consisting of 18 species of slow-growing mycobacteria. In 2009, a case of NTM-associated infectious skin disease was reported in Shiga Prefecture, Japan. The patient presented with scattered nodules on the chest, back and extremities, and an M. simiae-like organism was isolated from skin biopsy specimens obtained from one of these lesions. Based on several assessments, including multiple-gene analyses, biochemical characterization and drug susceptibility testing, we concluded that this isolate represented a novel species of NTM, and proposed the name 'Mycobacterium shigaense'. Since 2009, five more cases of NTM-associated infectious disease in which there was a suspected involvement of 'M. shigaense' have been reported. Interestingly, four of these six cases occurred in Shiga Prefecture. Here we performed multiple-gene phylogenetic analyses, physiological and biochemical characterization tests, drug susceptibility tests, and profiling of proteins, fatty acids and mycolic acids of eight clinical isolates from the six suspected 'M. shigaense' cases. The results confirmed that all of the clinical isolates were 'M. shigaense', a slow-growing, scotochromogenic species. Here M. shigaense is validly proposed as a new member of the M. simiae complex, with the type strain being UN-152
T (=JCM 32072T =DSM 46748T ).- Published
- 2018
- Full Text
- View/download PDF
24. Concurrent Autoimmune Neutropenia and Idiopathic Thrombocytopenic Purpura Associated with IgG4-related Diease.
- Author
-
Shimazu Y, Uchiyama T, Mizumoto C, Takeoka T, Tsuji M, Tomo K, Takaori K, Sakai N, Okuno T, and Ohno T
- Subjects
- Autoimmune Diseases immunology, Humans, Inflammation complications, Lung Diseases, Interstitial complications, Male, Middle Aged, Nephritis, Interstitial complications, Autoimmune Diseases complications, Immunoglobulin G blood, Neutropenia complications, Purpura, Thrombocytopenic, Idiopathic complications
- Abstract
IgG4-related disease (IgG4RD) is a multi-organ disorder characterized by an elevated serum IgG4 level and IgG4-positive plasma cell infiltration of the affected organs, accompanied by tissue fibrosis and sclerosis. Although it can affect any organ, to our knowledge, no cases involving concurrent autoimmune neutropenia and thrombocytopenia have been reported. A 62-year-old man visited our hospital and was diagnosed with IgG4RD accompanied by interstitial pneumonitis, lymphadenopathy, and interstitial nephritis. During his clinical course, he developed autoimmune neutropenia and idiopathic thrombocytopenic purpura. Our case, invoving multiple hematological abnormalities, might help deepen our understanding of the pathophysiology of IgG4RD.
- Published
- 2018
- Full Text
- View/download PDF
25. High pretransplant hepcidin levels are associated with poor overall survival and delayed platelet engraftment after allogeneic hematopoietic stem cell transplantation.
- Author
-
Sakamoto S, Kawabata H, Kanda J, Uchiyama T, Mizumoto C, Kitano T, Kondo T, Hishizawa M, Tomosugi N, and Takaori-Kondo A
- Subjects
- Adolescent, Adult, Aged, Female, Graft vs Host Disease epidemiology, Humans, Male, Middle Aged, Retrospective Studies, Survival Analysis, Transplantation, Homologous, Treatment Outcome, Young Adult, Hematologic Neoplasms blood, Hematologic Neoplasms therapy, Hematopoietic Stem Cell Transplantation adverse effects, Hepcidins blood
- Abstract
Iron overload is considered a risk factor for mortality in patients with hematopoietic malignancies. Hepcidin is a key regulator of systemic iron balance. We previously reported dynamic changes of serum hepcidin-25 levels in patients with hematologic malignancies after allogeneic hematopoietic stem cell transplantation (allo-HSCT). In this study, we retrospectively analyzed the association of pretransplant hepcidin-25 levels with overall survival (OS), engraftment, and other clinical outcomes of allo-HSCT in patients with hematologic malignancies. A total of 166 patients were divided into two groups depending on their pretransplant serum hepcidin-25 levels; their median age was 49.5 years, and the median follow-up time was 46.8 months. At 3 years, the patients in the high-hepcidin group had a significantly lower OS than those in the low-hepcidin group (49.2 vs. 69.0%, respectively; P = 0.006). Multivariate analysis revealed that pretransplant serum hepcidin-25 level, sex, and disease status were independently associated with OS. The incidence of platelet engraftment was significantly lower in the high-hepcidin group than in the low-hepcidin group, whereas no significant differences were observed in neutrophil and reticulocyte engraftments between these groups. Hence, pretransplant serum hepcidin levels can be a marker for predicting delayed platelet recovery after allo-HSCT., (© 2016 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.)
- Published
- 2017
- Full Text
- View/download PDF
26. Sequential Use of Second-Generation Tyrosine Kinase Inhibitor Treatment and Intensive Chemotherapy Induced Long-Term Complete Molecular Response in Imatinib-Resistant CML Patient Presenting as a Myeloid Blast Crisis.
- Author
-
Tsuji M, Uchiyama T, Mizumoto C, Takeoka T, Tomo K, and Ohno T
- Abstract
Myeloid blast crisis of chronic myeloid leukemia (CML-MBC) is rarely seen at presentation and has a poor prognosis. There is no standard therapy for CML-MBC. It is often difficult to distinguish CML-MBC from acute myeloid leukemia expressing the Philadelphia chromosome (Ph+ AML). We present a case in which CML-MBC was seen at the initial presentation in a 75-year-old male. He was treated with conventional AML-directed chemotherapy followed by imatinib mesylate monotherapy, which failed to induce response. However, he achieved long-term complete molecular response after combination therapy involving dasatinib, a second-generation tyrosine kinase inhibitor, and conventional chemotherapy.
- Published
- 2017
- Full Text
- View/download PDF
27. H-Ferritin Is Preferentially Incorporated by Human Erythroid Cells through Transferrin Receptor 1 in a Threshold-Dependent Manner.
- Author
-
Sakamoto S, Kawabata H, Masuda T, Uchiyama T, Mizumoto C, Ohmori K, Koeffler HP, Kadowaki N, and Takaori-Kondo A
- Subjects
- Animals, Biological Transport, CHO Cells, Cell Line, Tumor, Cell Membrane metabolism, Cricetinae, Cricetulus, Ferritins metabolism, Humans, Antigens, CD metabolism, Apoferritins metabolism, Erythroid Cells metabolism, Receptors, Transferrin metabolism
- Abstract
Ferritin is an iron-storage protein composed of different ratios of 24 light (L) and heavy (H) subunits. The serum level of ferritin is a clinical marker of the body's iron level. Transferrin receptor (TFR)1 is the receptor not only for transferrin but also for H-ferritin, but how it binds two different ligands and the blood cell types that preferentially incorporate H-ferritin remain unknown. To address these questions, we investigated hematopoietic cell-specific ferritin uptake by flow cytometry. Alexa Fluor 488-labeled H-ferritin was preferentially incorporated by erythroid cells among various hematopoietic cell lines examined, and was almost exclusively incorporated by bone marrow erythroblasts among human primary hematopoietic cells of various lineages. H-ferritin uptake by erythroid cells was strongly inhibited by unlabeled H-ferritin but was only partially inhibited by a large excess of holo-transferrin. On the other hand, internalization of labeled holo-transferrin by these cells was not inhibited by H-ferritin. Chinese hamster ovary cells lacking functional endogenous TFR1 but expressing human TFR1 with a mutated RGD sequence, which is required for transferrin binding, efficiently incorporated H-ferritin, indicating that TFR1 has distinct binding sites for H-ferritin and holo-transferrin. H-ferritin uptake by these cells required a threshold level of cell surface TFR1 expression, whereas there was no threshold for holo-transferrin uptake. The requirement for a threshold level of TFR1 expression can explain why among primary human hematopoietic cells, only erythroblasts efficiently take up H-ferritin.
- Published
- 2015
- Full Text
- View/download PDF
28. An AKI biomarker lipocalin 2 in the blood derives from the kidney in renal injury but from neutrophils in normal and infected conditions.
- Author
-
Kanda J, Mori K, Kawabata H, Kuwabara T, Mori KP, Imamaki H, Kasahara M, Yokoi H, Mizumoto C, Thoennissen NH, Koeffler HP, Barasch J, Takaori-Kondo A, Mukoyama M, and Nakao K
- Subjects
- Acute-Phase Proteins urine, Animals, Bacterial Infections blood, Bacterial Infections urine, Biomarkers blood, Biomarkers urine, CCAAT-Enhancer-Binding Proteins genetics, CCAAT-Enhancer-Binding Proteins physiology, Hematologic Neoplasms complications, Hematologic Neoplasms therapy, Hematopoietic Stem Cell Transplantation, Humans, Lipocalin-2, Lipocalins urine, Mice, Mice, Knockout, Molecular Weight, Oncogene Proteins urine, Acute Kidney Injury blood, Kidney metabolism, Lipocalins blood, Neutrophils metabolism, Oncogene Proteins blood
- Abstract
Background: Lipocalin 2 (LCN2 or neutrophil gelatinase-associated lipocalin) is a secretory protein discovered from neutrophils, which accumulates in the blood and urine during acute kidney injury (AKI) and in the blood by bacterial infection. Little is known about the tissue source and molecular forms of this protein under normal and pathophysiologic conditions., Methods: By sandwich ELISA, serum and urinary LCN2 levels were measured in 36 patients with hematologic malignancies who transiently became neutropenic by stem cell transplantation (SCT). To evaluate contribution of neutrophil-derived LCN2 in the physiologic blood LCN2 concentrations, we examined CCAAT/enhancer-binding protein ε (C/EBPε) knockout mice, which lack mature neutrophils., Results: In patients without AKI and bacterial infection, at 1 week after SCT, the median blood neutrophil counts became zero and serum LCN2 levels were decreased by 76 ± 6 % (p < 0.01), but urinary LCN2 levels were not altered. During neutropenic conditions, bacterial infection caused only a modest rise of serum LCN2 but AKI produced a marked rise of serum and urinary LCN2 levels. Serum LCN2 concentrations in C/EBPε knockout mice were reduced by 66 ± 11 % compared to wild-type mice (p < 0.05). Blood LCN2 existed predominantly in high molecular weight forms (>100 kDa), while urinary LCN2 was mainly in low molecular weight forms., Conclusion: Our findings suggest that neutrophils are the major source of circulating LCN2 in normal and infected conditions, whereas blood and urinary LCN2 mainly derive from the kidney during AKI, and that the molecular forms and regulation of blood and urinary LCN2 are clearly distinct.
- Published
- 2015
- Full Text
- View/download PDF
29. Differing impacts of pretransplant serum ferritin and C-reactive protein levels on the incidence of chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
- Author
-
Sakamoto S, Kawabata H, Kanda J, Uchiyama T, Mizumoto C, Kondo T, Yamashita K, Ichinohe T, Ishikawa T, Kadowaki N, and Takaori-Kondo A
- Subjects
- Acute Disease, Adolescent, Adult, Aged, Chronic Disease, Female, Graft vs Host Disease mortality, Humans, Male, Middle Aged, Proportional Hazards Models, Recurrence, Retrospective Studies, Transplantation, Homologous, Young Adult, C-Reactive Protein metabolism, Ferritins blood, Graft vs Host Disease etiology, Hematopoietic Stem Cell Transplantation adverse effects
- Abstract
Studies have suggested an association between pretransplant serum levels of ferritin and C-reactive protein (CRP) and complications of allogeneic hematopoietic stem cell transplantation (HSCT). To evaluate the prognostic impact of these biomarkers on the development of acute and chronic graft-versus-host disease (GVHD), we retrospectively studied 211 patients who underwent allogeneic HSCT for hematologic diseases at our institution. The cumulative incidence rate of chronic GVHD at 3 years was 40.7 %. In the multivariate analysis, elevated CRP levels (≥2 mg/L) were significantly associated with a high incidence of chronic GVHD, whereas high ferritin levels (≥880 ng/mL) showed a tendency, though not statistically significant, to association with a low incidence of chronic GVHD. No significant association was observed between the pretransplant serum ferritin or CRP levels and the incidence of acute GVHD. Multivariate analysis indicated that high pretransplant serum ferritin levels were significantly associated with increases in treatment-related mortality and relapse rates. Overall, an elevated pretransplant serum ferritin level, but not an elevated serum CRP level, is a strong risk factor for overall mortality (hazard ratio, 2.16; P = 0.002). Our results also indicate that pretransplant serum CRP levels may be a useful biomarker for predicting the risk of chronic GVHD.
- Published
- 2013
- Full Text
- View/download PDF
30. Acidic milieu augments the expression of hepcidin, the central regulator of iron homeostasis.
- Author
-
Mizumoto C, Kawabata H, Uchiyama T, Sakamoto S, Kanda J, Tomosugi N, and Takaori-Kondo A
- Subjects
- Antimicrobial Cationic Peptides genetics, Carbon Dioxide pharmacology, Carcinoma, Hepatocellular pathology, Cell Line, Tumor drug effects, Cell Line, Tumor metabolism, Cellular Microenvironment, Gene Expression Regulation, Leukemic drug effects, Hepcidins, Homeostasis drug effects, Humans, Hydrochloric Acid pharmacology, Hydrogen-Ion Concentration, Iron-Regulatory Proteins biosynthesis, Iron-Regulatory Proteins genetics, K562 Cells drug effects, K562 Cells metabolism, Lactic Acid pharmacology, Liver Neoplasms pathology, Neoplasm Proteins biosynthesis, Neoplasm Proteins genetics, Promoter Regions, Genetic, RNA, Messenger biosynthesis, RNA, Neoplasm biosynthesis, Acids pharmacology, Antimicrobial Cationic Peptides biosynthesis, Gene Expression Regulation, Neoplastic drug effects, Iron metabolism, Up-Regulation drug effects
- Abstract
Hepcidin is the central regulator of body iron homeostasis, and dysregulation of hepcidin expression causes various clinical disorders, such as anemia and hemochromatosis. Various stimuli, including iron load and interleukin-6, are involved in the regulation of hepcidin expression. We previously reported that serum hepcidin levels were high in patients with end-stage renal disease, compared with healthy subjects. Since metabolic acidosis is commonly observed in these patients, we hypothesized that acidic milieu might augment hepcidin expression. In this study, we investigated the effect of changes in the pH of the microenvironment on hepcidin expression in human hepatoma and leukemia cell lines. We found that hepcidin expression in these cells was augmented by the acidic milieu created with lactic acid, hydrochloric acid and excess carbon dioxide. Acidic milieu did not clearly enhance hepcidin promoter activity, but rather stabilized hepcidin transcript in the hepatoma cells. We speculate that metabolic acidosis may contribute in part to the elevation of serum hepcidin levels in patients with end-stage chronic kidney disease. Further studies are needed to elucidate the association between acidosis and hepcidin expression in various clinical settings.
- Published
- 2012
- Full Text
- View/download PDF
31. Immune pancytopenia associated with a leukemic B-cell tumor carrying t(14;18)(q32;q21) translocation.
- Author
-
Mizumoto C, Ohno H, Katsurada T, Oguma S, and Yoshida Y
- Subjects
- Aged, Antibodies, Monoclonal, Murine-Derived therapeutic use, Antineoplastic Agents therapeutic use, Autoimmune Diseases diagnosis, Humans, Leukemia, B-Cell drug therapy, Male, Pancytopenia diagnosis, Rituximab, Treatment Outcome, Autoimmune Diseases etiology, Chromosomes, Human, Pair 14 genetics, Chromosomes, Human, Pair 18 genetics, Leukemia, B-Cell complications, Leukemia, B-Cell genetics, Pancytopenia etiology, Translocation, Genetic genetics
- Abstract
We report a 75-year-old man who was initially suggested to have acute leukemia. The hemoglobin level was 3.8 g/dL, white cell count was 7,700/µL with an absence of mature neutrophils and 69.0% leukemic cells, and platelet was 0.4 × 10(4)/µL. Coombs' antiglobulin test was positive. Leukemic cells were CD5(-), CD10(+), CD20(+), CD23(-), and IgG/λ(dim+). The bone marrow consisted of normal hematopoietic precursors, whereas fluorescence in situ hybridization detected the BCL2/IgH fusion gene. He was treated with rituximab-containing chemotherapy, resulting in the resolution of pancytopenia. The underlying disease was a leukemic B-cell tumor with t(14;18)(q32;q21), and the pancytopenia was mainly caused by autoimmune mechanisms.
- Published
- 2011
- Full Text
- View/download PDF
32. Numerous aggregates of "tiny" micromegakaryocytes in the bone marrow.
- Author
-
Yoshida Y, Hamakawa Y, Oguma S, Katsurada T, Mizumoto C, and Ohno H
- Subjects
- Aged, Cell Adhesion, Cell Size, Humans, Leukocytosis pathology, Male, Thrombocytosis pathology, Bone Marrow pathology, Megakaryocytes pathology
- Published
- 2010
- Full Text
- View/download PDF
33. The duration of functioning of a subcutaneous implantable port for the treatment of hematological tumors: a single institution-based study.
- Author
-
Ohno H, Mizumoto C, Otsuki Y, Oguma S, and Yoshida Y
- Subjects
- Adult, Aged, Antineoplastic Agents adverse effects, Catheter-Related Infections etiology, Catheterization, Central Venous adverse effects, Device Removal, Equipment Design, Female, Hematologic Neoplasms mortality, Humans, Infusions, Intravenous, Kaplan-Meier Estimate, Male, Middle Aged, Neutropenia etiology, Prospective Studies, Time Factors, Treatment Outcome, Antineoplastic Agents administration & dosage, Catheterization, Central Venous instrumentation, Catheters, Indwelling adverse effects, Hematologic Neoplasms drug therapy, Infusion Pumps, Implantable adverse effects, Subclavian Vein
- Abstract
Background: Although subcutaneous implantable ports have been indicated as venous access for chemotherapy, these devices have not been used routinely for hematological tumors., Methods: Between May 2006 and April 2009, 39 ports were implanted in 37 patients with hematological tumors and 16 ports were implanted in 14 patients with nonhematological tumors. The patients were treated with standard/first-line and/or salvage/second-line or greater chemotherapy, and were prospectively followed until port removal, death, or the end of the study., Results: Thirty-five (96%) patients with hematological tumors developed grade 4 hematological toxicity, while 1 (7%) patient with nonhematological tumors showed grade 4 neutropenia. The actual duration of the port in situ ranged from 14 to 719 days (mean, 271.4 days) in the hematology group, and from 50 to 955 days (mean, 419.5 days) in the nonhematology group (P = 0.039). The Kaplan-Meier-estimated median duration of port in situ in the hematology group was 364 days, which was significantly shorter than that in the nonhematology group (P = 0.009). When patient death and port removal for the end of treatment were censored, the rate of port functioning at 1 year was estimated to be 83% in the hematology group. Bloodstream infection (BSI) occurred in 7 patients with hematological tumors and in 1 patient with metastatic colorectal cancer; however, microbiological confirmation that the implantable port was the source of the BSI was inconclusive., Conclusion: The duration of port functioning in patients with hematological tumors was comparable to that in patients with nonhematological tumors. The higher rate of BSI in the hematology group was primarily attributable to profound neutropenia.
- Published
- 2010
- Full Text
- View/download PDF
34. Clinical significance of serum hepcidin levels on early infectious complications in allogeneic hematopoietic stem cell transplantation.
- Author
-
Kanda J, Mizumoto C, Kawabata H, Ichinohe T, Tsuchida H, Tomosugi N, Matsuo K, Yamashita K, Kondo T, Ishikawa T, and Uchiyama T
- Subjects
- Adult, Bacterial Infections diagnosis, Bacterial Infections etiology, Biomarkers blood, Cytomegalovirus Infections diagnosis, Cytomegalovirus Infections etiology, Female, Hematologic Neoplasms therapy, Hepcidins, Humans, Iron Overload complications, Male, Middle Aged, Opportunistic Infections diagnosis, Risk, Transplantation, Homologous, Young Adult, Antimicrobial Cationic Peptides blood, Hematopoietic Stem Cell Transplantation adverse effects, Opportunistic Infections etiology, Predictive Value of Tests
- Abstract
The association of iron overload with complications of allogeneic hematopoietic stem cell transplantation (HSCT) has been suggested in previous studies. Because hepcidin plays a central role in the regulation of iron homeostasis, we analyzed the association between pretransplant serum hepcidin-25 levels and early infectious complications after allogeneic HSCT. We studied 55 consecutive adult patients with a median age of 47 years (range: 20-64 years) who underwent allogeneic HSCT for hematologic malignancies at our institution. Thirty-two patients had myelogenous malignancies; the remaining 23 had lymphogenous malignancies. The median pretransplant serum hepcidin level of patients in the study was 21.6 ng/mL (range: 1.4-371 ng/mL), which was comparable to that of healthy volunteers (median: 19.1 ng/mL [range: 2.3-37 ng/mL]; n = 17). When cumulative incidences of documented bacterial and cytomegalovirus (CMV) infections at day 100 were compared according to pretransplant hepcidin-25 levels, the incidence of bacterial, but not CMV, infection, was significantly higher in the high-hepcidin group (> or = 50 ng/mL; n = 17) than in the low-hepcidin group (<50 ng/mL; n = 38) (65% [95% confidence interval, 38%-82%] versus 11% [3%-23%]; P < .001). This finding was confirmed by multivariate Cox analysis adjusted for confounders, including pretransplant ferritin and C-reactive protein (CRP) levels. No fungal infection was documented in either group. These results suggest that the pretransplant serum hepcidin-25 level may be a useful marker for predicting the risk of early bacterial complications after allogeneic HSCT. Larger prospective studies are, however, warranted to confirm our findings.
- Published
- 2009
- Full Text
- View/download PDF
35. MALT lymphoma of the thymus with Sjögren's syndrome: biphasic changes in serological abnormalities over a 4-year period following thymectomy.
- Author
-
Sakamoto T, Yamashita K, Mizumoto C, Ueda M, Takeoka T, Hishita T, Hada S, and Ohno T
- Subjects
- Aged, B-Lymphocytes pathology, Female, Humans, Lymphoma, B-Cell, Marginal Zone diagnosis, Lymphoma, B-Cell, Marginal Zone surgery, Thymectomy, Thyroid Neoplasms diagnosis, Thyroid Neoplasms surgery, Treatment Outcome, Lymphoma, B-Cell, Marginal Zone complications, Sjogren's Syndrome diagnosis, Thyroid Neoplasms complications
- Abstract
Thymic mucosa-associated lymphoid tissue (MALT) lymphoma shows distinct immunological characteristics, such as the expression of the IgA isotype, the frequent presence of immunoglobulin abnormalities, and a strong association with autoimmune disease, especially Sjögren's syndrome (SjS). We report a case of thymic MALT lymphoma, who exhibited biphasic changes in her clinical characteristics during the 4-year observation period after thymectomy. A 71-year-old woman was admitted because of suspected SjS. A diagnosis of primary thymic MALT lymphoma was made, and SjS was confirmed. Serological abnormalities such as polyclonal hypergammaglobulinemia, IgA M protein, and elevated levels of rheumatoid factor were noted. These abnormalities improved rapidly after the thymectomy, but did not completely disappear. Interestingly, the remaining abnormalities, which can be ascribed to the proliferation of B cells throughout the body under the influence of SjS, have been improving slowly but steadily during the 4-year observation period. It is suspected that the removal of the tumor by thymectomy has more or less normalized the immunological environment and alleviated the SjS disease activity.
- Published
- 2009
- Full Text
- View/download PDF
36. Mycophenolate mofetil combined with tacrolimus and minidose methotrexate after unrelated donor bone marrow transplantation with reduced-intensity conditioning.
- Author
-
Mizumoto C, Kanda J, Ichinohe T, Ishikawa T, Matsui M, Kadowaki N, Kondo T, Imada K, Hishizawa M, Kawabata H, Nishikori M, Yamashita K, Takaori-Kondo A, Hori T, and Uchiyama T
- Subjects
- Acute Disease, Adult, Aged, Chronic Disease, Dose-Response Relationship, Drug, Graft vs Host Disease drug therapy, Graft vs Host Disease immunology, Humans, Leukemia immunology, Leukemia surgery, Methotrexate adverse effects, Middle Aged, Mycophenolic Acid adverse effects, Mycophenolic Acid pharmacology, Survival Rate, Tacrolimus adverse effects, Bone Marrow Transplantation immunology, Methotrexate pharmacology, Mycophenolic Acid analogs & derivatives, Tacrolimus pharmacology, Transplantation Conditioning
- Abstract
We evaluated the efficacy of a post-grafting immunosuppressive regimen consisting of tacrolimus, methotrexate, and mycophenolate mofetil (MMF) in 21 adults (median age, 55 years) with poor-risk hematologic malignancy who underwent unrelated bone marrow transplantation after fludarabine-based reduced-intensity conditioning (RIC). In combination with intravenous tacrolimus and minidose methotrexate (5 mg/m2 on days 1, 3, and 6), MMF was orally administered at 30 mg/kg daily in three divided doses between days 7 and 27. All patients achieved neutrophil recovery with donor-type chimerism at a median of 19 days (range, 13-35). Cumulative incidences of grades II-IV and III-IV acute graft-versus-host disease (GVHD) were 33% (95% CI, 15-53%) and 5% (95% CI, 0.3-20%), respectively. Five of 20 evaluable patients developed extensive chronic GVHD. Toxicities associated with the use of MMF were acceptable, although one patient experienced intractable GVHD immediately after the cessation of MMF. With a median follow-up of 24 months, overall survival at 3 years was 38% (95% CI, 14-63%). No late graft failure was observed. In conclusion, post-transplant MMF combined with tacrolimus and methotrexate was well tolerated and conferred stable donor cell engraftment, low risk of severe acute GVHD, and encouraging overall survival in unrelated donor marrow transplantation after RIC regimens.
- Published
- 2009
- Full Text
- View/download PDF
37. Streptococcal emm types in Hawaii: a region with high incidence of acute rheumatic fever.
- Author
-
Erdem G, Mizumoto C, Esaki D, Abe L, Reddy V, and Effler PV
- Subjects
- Acute Disease, Hawaii epidemiology, Humans, Pharynx microbiology, Rheumatic Fever epidemiology, Streptococcal Infections epidemiology, Streptococcal Vaccines genetics, Streptococcus pyogenes genetics, Streptococcus pyogenes isolation & purification, Antigens, Bacterial genetics, Bacterial Outer Membrane Proteins genetics, Carrier Proteins genetics, Rheumatic Fever microbiology, Streptococcal Infections microbiology, Streptococcus pyogenes classification
- Abstract
Background: The clinical epidemiology of group A streptococcal (GAS) infections in Hawaii seems different from that in the continental United States with frequent skin infections and endemically high rates of acute rheumatic fever (ARF)., Methods: GAS emm types in Hawaii were determined to identify any possible association between the emm types and specific clinical manifestations. A convenience sample of 1482 Hawaii GAS isolates collected between February 2000 and December 2005 was used. All isolates were characterized by emm sequence typing. The distribution of emm types in Hawaii was compared with the published continental US data for pharyngeal and invasive GAS strains, the CDC database from similar time periods, as well as with emm types present in a candidate GAS vaccine., Results: Ninety-three distinct emm types were recognized among the 1482 GAS isolates. The most frequently identified emm types in order of decreasing frequency were 12, 1, 28, 4, 22, 77, 81, 58, 65/69, 49, 74, 85, 92, 75, 101 and 2. Of this study sample, 27 of the 50 invasive GAS isolates belonged to uncommon continental US emm types (54% in Hawaii cultures vs. 10% reported from the continental US). Of the 1179 pharyngeal isolates, 509 belonged uncommon continental US emm types (43% in Hawaii cultures vs. 27% reported from the continental US)., Conclusions: The prevalent emm types in Hawaii differ from those in the continental US. The prevalence of these unusual emm types might limit the effectiveness of any proposed multivalent type-specific GAS vaccine in Hawaii.
- Published
- 2009
- Full Text
- View/download PDF
38. Serum hepcidin level and erythropoietic activity after hematopoietic stem cell transplantation.
- Author
-
Kanda J, Mizumoto C, Kawabata H, Tsuchida H, Tomosugi N, Matsuo K, and Uchiyama T
- Subjects
- Adult, Female, Hematologic Neoplasms blood, Hematologic Neoplasms surgery, Hepcidins, Humans, Male, Antimicrobial Cationic Peptides blood, Erythropoiesis, Hematopoietic Stem Cell Transplantation
- Abstract
The relationship between serum hepcidin, a key regulator of body iron homeostasis, and erythropoiesis was investigated before and after stem cell transplantation in 31 patients with hematopoietic malignancies. Serum hepcidin-25 was monitored using a liquid chromatography-tandem mass spectrometry-based assay system. Other iron- and erythropoiesis-related parameters and known hepcidin regulators, such as interleukin-6 and growth differentiation factor-15, were also monitored. The serum hepcidin level peaked one week after stem cell transplantation, followed by a gradual decrease with a parallel change in interleukin-6 and a reciprocal change in reticulocyte count. Multivariate regression analysis demonstrated that the serum hepcidin level at four weeks after stem cell transplantation showed significant inverse correlations with erythropoietic activity markers, such as the soluble transferrin receptor, but not with growth differentiation factor-15. These results indicate the existence of an unknown functional erythropoiesis-associated circulating factor, other than growth differentiation factor-15, that negatively regulates hepcidin production in stem cell transplantation settings.
- Published
- 2008
- Full Text
- View/download PDF
39. High-resolution computed tomography findings of diffuse pulmonary involvement by mycosis fungoides.
- Author
-
Tamai K, Koyama T, Kondo T, Takaori A, Mizumoto C, Manabe T, and Togashi K
- Subjects
- Fatal Outcome, Humans, Male, Middle Aged, Mycosis Fungoides pathology, Skin Neoplasms pathology, Lung Neoplasms diagnostic imaging, Lung Neoplasms secondary, Mycosis Fungoides diagnostic imaging, Skin Neoplasms diagnostic imaging, Tomography, X-Ray Computed
- Abstract
The authors describe a case of diffuse pulmonary involvement by mycosis fungoides in a 55-year-old man who presented with progressive exertional dyspnea. Although he had a long history of skin lesions, mycosis fungoides remained undiagnosed at initial presentation. High-resolution computed tomography revealed hazy ground-glass opacities along the thickened bronchovascular bundles and interlobular septa, particularly in the mid and upper lung fields, and traction bronchiectasis in the central regions. Skin biopsy confirmed the diagnosis of mycosis fungoides in the plaque stage. Transbronchial lung biopsy revealed diffuse infiltration of the atypical lymphoid cells in the peribronchial and perivascular regions. In this case, high-resolution computed tomography played an important role for suggesting the lymphoproliferative disease in this patient with undiagnosed mycosis fungoides.
- Published
- 2007
- Full Text
- View/download PDF
40. Group A streptococcal isolates temporally associated with acute rheumatic fever in Hawaii: differences from the continental United States.
- Author
-
Erdem G, Mizumoto C, Esaki D, Reddy V, Kurahara D, Yamaga K, Abe L, Johnson D, Yamamoto K, and Kaplan EL
- Subjects
- Acute Disease, Adolescent, Anti-Bacterial Agents therapeutic use, Child, Child, Preschool, Ethnicity, Hawaii, Humans, Incidence, Rheumatic Fever drug therapy, Rheumatic Fever epidemiology, Streptococcal Infections drug therapy, United States, Penicillins therapeutic use, Rheumatic Fever microbiology, Streptococcal Infections epidemiology, Streptococcal Infections physiopathology, Streptococcus pyogenes classification, Streptococcus pyogenes isolation & purification
- Abstract
Background: The annual incidence of acute rheumatic fever (ARF) in Hawaii has remained several times higher than that in the continental United States, particularly among ethnic Polynesians. The emm types of Streptococcus pyogenes that are associated with this nonsuppurative complication have, to our knowledge, not been previously reported in Hawaii., Methods: Patients with ARF were identified through an active surveillance system at Kapiolani Medical Center (Honolulu, HI), the only pediatric tertiary care referral hospital in Hawaii. Specimens were obtained by throat culture from patients who met the Jones criteria for ARF at the time of presentation (63 patients), prior to penicillin treatment, and from consenting family contacts (10 individuals). Eight patients and 2 close family contacts with positive throat culture results were identified from February 2000 through December 2005. Group A streptococci isolates were characterized by emm sequence typing., Results: Unusual emm types were temporally associated with the onset of ARF. Emm types 65/69 (from 2 patients), 71, 92, 93, 98, 103, and 122 were isolated from the 8 patients with ARF, and emm types 52 and 101 were isolated from the 2 household contacts., Conclusions: So-called rheumatogenic emm types and/or serotypes, which were previously associated with ARF in the continental United States, were not found in this study. Instead, emm types that are not commonly included among group A streptococci isolates in the continental United States and that are seldom, if ever, temporally associated with ARF were identified. These findings suggest that unusual group A streptococci emm types play a significant role in the epidemiology of ARF in Hawaii.
- Published
- 2007
- Full Text
- View/download PDF
41. Leukemic and meningeal relapse of CD5+ intravascular large B-cell lymphoma with down-modulation of CD20 after rituximab therapy.
- Author
-
Ohno T, Sakamoto T, Mizumoto C, Miyoshi T, Ueda M, Takeoka T, Yamashita K, Hishita T, and Hada S
- Subjects
- Antibodies, Monoclonal administration & dosage, Antibodies, Monoclonal, Murine-Derived, Female, Gene Expression Regulation, Leukemic drug effects, Humans, Lymphocytes metabolism, Lymphocytes pathology, Lymphoma, B-Cell cerebrospinal fluid, Lymphoma, B-Cell pathology, Meningeal Neoplasms cerebrospinal fluid, Meningeal Neoplasms pathology, Middle Aged, Recurrence, Remission Induction, Rituximab, Antigens, CD20 cerebrospinal fluid, Antineoplastic Combined Chemotherapy Protocols administration & dosage, CD5 Antigens cerebrospinal fluid, Lymphoma, B-Cell prevention & control, Meningeal Neoplasms prevention & control, Tumor Escape drug effects
- Abstract
Although CD20- relapses of B-cell lymphoma following rituximab therapy have increasingly been reported recently, coexistence of both the original and selected clones on relapse in a single patient have not been described. We experienced such a case with rare CD5+ intravascular lymphomatosis (IVL). A 46-year-old woman was admitted because of IVL complicated with cauda equina syndrome and pulmonary infarction. Complete remission was successfully achieved with multidrug chemotherapy in combination with rituximab. However, the disease recurred after 8 months with leukemic progression and meningeal involvement. The phenotype of the abnormal lymphocytes in the peripheral blood was fundamentally the same (CD20+CD5+CD10-CD19+CD23-sIglambda+) as that of the cells in the cerebrospinal fluid (CSF). However, CD20 expression was decreased remarkably compared with that in the CSF and that in the bone marrow before therapy. The targeting of CD20 molecules on the tumor cell surface by rituximab may have provided a selective pressure on lymphoma cells. The escape phenomenon of the lymphoma cells from rituximab was observed by simultaneously comparing the CD20 expression of cells in the peripheral blood and in a site of sanctuary from rituximab, the CSF.
- Published
- 2006
- Full Text
- View/download PDF
42. Characterization of a community cluster of group a streptococcal invasive disease in Maui, Hawaii.
- Author
-
Erdem G, Abe L, Kanenaka RY, Pang L, Mills K, Mizumoto C, Yamaga K, and Effler PV
- Subjects
- Antigens, Bacterial, Bacterial Outer Membrane Proteins genetics, Bacterial Typing Techniques, Carrier Proteins, Disease Outbreaks, Fasciitis, Necrotizing epidemiology, Female, Hawaii epidemiology, Humans, Male, Serotyping, Streptococcal Infections epidemiology, Streptococcus pyogenes isolation & purification, Fasciitis, Necrotizing microbiology, Streptococcal Infections microbiology
- Abstract
A community cluster of severe group A streptococcal skin infections occurred in Maui, Hawaii with 3 fatal cases of necrotizing fasciitis in 2002. emm types 1, 12, 58, 74, 85 and 109 were identified from 8 patients. emm types 74 and 109 have not been previously described in the United States according to the Centers for Disease Control and Prevention database. The identification of uncommon emm types suggested that group A streptococcal sero-types in Hawaii are different from those in the continental United States and can result in serious disease.
- Published
- 2004
- Full Text
- View/download PDF
43. EEG activity of aviators during imagery flight training.
- Author
-
Tokumaru O, Mizumoto C, Takada Y, and Ashida H
- Subjects
- Adult, Alpha Rhythm, Analysis of Variance, Brain Mapping, Electrodes, Evoked Potentials physiology, Humans, Japan, Male, Aerospace Medicine, Cortical Synchronization, Eidetic Imagery physiology, Learning physiology, Mental Processes physiology, Military Personnel
- Abstract
Objective: Imagery flight training (IFT) is widely used in aviation without neurophysiological evaluation. Electroencephalogram (EEG) during IFT was compared between experienced fighter pilots (FP) and novice pilots (NP)., Methods: Six FP and 9 NP performed imagery right bank, left bank, right roll, and left roll maneuvers. Each task was repeated 5 times in a random order. Instantaneous EEG power was calculated by the intertrial variance method., Results: In FP, 3 waves of event-related desynchronization (ERD) were observed. The third ERD (ERD3) was observed at all the electrode positions except Fp1 which began 0.25 s before the beginning of IFT and reached its peak 0.25 s after the beginning of IFT. In NP, ERD was not related to the start of IFT. The difference in event-related EEG at the peak of ERD3 was not significant between FP and NP. However, the negative change to the peak of ERD3 was significantly larger in FP than in NP., Conclusions: It is speculated that ERD3 in FP may indicate the activation of cortical areas including visual- and motor-related areas involved in IFT., Significance: It is speculated that the representation of IFT was programmed in visual- and motor-related cortical areas as an aviator's career advances.
- Published
- 2003
- Full Text
- View/download PDF
44. Vector analysis of electrogastrography during motion sickness.
- Author
-
Tokumaru O, Mizumoto C, Takada Y, Tatsuno J, and Ashida H
- Subjects
- Adult, Analysis of Variance, Electrophysiology, Female, Humans, Male, Middle Aged, Motion Sickness etiology, Physical Stimulation methods, Postprandial Period physiology, Coriolis Force, Electrodiagnosis methods, Gastrointestinal Motility physiology, Motion Sickness physiopathology, Rotation adverse effects, Stomach physiology
- Abstract
Although the dominant frequency at 3 cpm of electrogastrography (EGG) is reported to shift to a higher frequency during motion sickness (MS), it is unclear whether the normal slow wave (NSW) disappears or not. The authors investigated changes in NSW using vector analysis of EGG. Fourteen subjects were exposed to a Coriolis stimulation to evoke MS. EGG was recorded from two sets of bipolar leads, placed perpendicular to each other representing x and y axes. Trajectories for each frequency were drawn on the x-y plane. The amplitude and phase difference at NSW were compared before, during, and after the stimulus for each subject. In those with a change in phase difference, changes in NSW and tachygastria were negatively correlated (P = -0.048), whereas in those without a change, they were not correlated. This indicated two different kinds of tachygastria due to MS: tachygastria with and without a change in NSW.
- Published
- 2003
- Full Text
- View/download PDF
45. Visual influence on the magnitude of somatogravic illusion evoked on advanced spatial disorientation demonstrator.
- Author
-
Tokumaru O, Kaida K, Ashida H, Mizumoto C, and Tatsuno J
- Subjects
- Adult, Humans, Male, Orientation, Photic Stimulation, Aerospace Medicine, Aviation, Optical Illusions, Visual Perception
- Abstract
Background: The somatogravic illusion (SGI) is a kind of spatial disorientation caused by a linear sustained acceleration. Pilots believe that visual cues, such as a visible horizon or texture flow, reduce this illusion. This study was performed to evaluate the influence of visual stimuli on the SGI using the Advanced Spatial Disorientation Demonstrator (ASDD)., Methods: There were eight healthy males who were exposed to a 0.58 g x axis linear acceleration on the ASDD, where the direction of the resultant gravitoinertial force was equivalent to 30 degrees pitch-up. One of the following visual stimuli was presented during each acceleration: BLANK (no visual cues); HORIZON (a visible horizon without motion); and TEXTURE (vertical lines moving toward the subject evoking vection). The subjective magnitude of the SGI in ordinal scale was observed; and in interval scale, the deviation of the moving point kept at the subjective horizon was observed. The differences among visual stimuli were analyzed., Results: The subjective magnitude of the SGI (p < 0.01) and the deviation of the moving point (p < 0.05) were significantly smaller in HORIZON than in BLANK and TEXTURE. No difference was demonstrated between BLANK and TEXTURE. The linear vection produced by the TEXTURE stimulus did not affect the SGI., Conclusion: The data indicated that the presence of a visible horizon reduced the magnitude of the SGI. On the other hand, the presence of a vection stimulus did not influence the magnitude of the SGI.
- Published
- 1998
46. Repression of motility and flagellin production at 37 degrees C is stronger in Listeria monocytogenes than in the nonpathogenic species Listeria innocua.
- Author
-
Kathariou S, Kanenaka R, Allen RD, Fok AK, and Mizumoto C
- Subjects
- Antibodies, Bacterial, Antibodies, Monoclonal, Antibody Specificity, Blotting, Western, Cell Movement, Enzyme-Linked Immunosorbent Assay, Flagellin immunology, Listeria metabolism, Listeria pathogenicity, Listeria monocytogenes metabolism, Listeria monocytogenes pathogenicity, Temperature, Virulence, Flagellin biosynthesis, Listeria physiology, Listeria monocytogenes physiology
- Abstract
Listeria monocytogenes and Listeria innocua differ markedly in virulence but are indistinguishable by classical taxonomic criteria. Both species are actively motile and produce abundant flagellin at 22 degrees C. We have found, however, noticeable differences between L. monocytogenes and L. innocua in motility and flagellin production at 37 degrees C. At this temperature, L. monocytogenes strains were virtually nonmotile and produced little or no detectable flagellin, whereas strains of L. innocua were frequently motile and produced substantial amounts of flagellin. This flagellin was recognized by a Listeria genus-specific monoclonal antibody that also recognized flagellin produced at 22 degrees C. These results suggest differential regulation of flagellin production between L. monocytogenes and L. innocua at 37 degrees C.
- Published
- 1995
- Full Text
- View/download PDF
47. Monoclonal antibodies with a high degree of specificity for Listeria monocytogenes serotype 4b.
- Author
-
Kathariou S, Mizumoto C, Allen RD, Fok AK, and Benedict AA
- Subjects
- Animals, Antibody Specificity, Antigens, Bacterial, Fluorescent Antibody Technique, Food Microbiology, Hot Temperature, Humans, Listeria monocytogenes classification, Listeria monocytogenes ultrastructure, Listeriosis microbiology, Mice, Serotyping, Antibodies, Monoclonal, Listeria monocytogenes immunology
- Abstract
Strains of Listeria monocytogenes serotype 4b account for a large fraction of sporadic listeriosis cases, as well as all major food-borne epidemics attributed to this pathogen. We have identified a set of three monoclonal antibodies which showed a high degree of specificity for strains of L. monocytogenes serotype 4b. Two of these antibodies (c74.33 and c74.180, isotypes immunoglobulin M [IgM] and IgG3, respectively) recognized all serotype 4b strains, whereas antibody c74.22 (isotype IgG1) failed to recognize certain epidemic-associated strains. The corresponding antigens were located on the surface of the bacteria and were expressed following bacterial growth in different media and over a wide range of temperatures (4, 22, and 37 degrees C). Heating L. monocytogenes cells at 80,90, or 100 degrees C abolished reactivity for c74.22 but not for c74.33 MAb. These MAbs were negative for all of the non-Listeria strains tested, including representatives of several gram-negative and gram-positive species. The surface antigen recognized by c74.22 appeared to be associated with the ability of the bacteria to enter (invade) mammalian cells in culture.
- Published
- 1994
- Full Text
- View/download PDF
48. Multiple echo SSFP sequences.
- Author
-
Mizumoto CT and Yoshitome E
- Subjects
- Humans, Models, Structural, Magnetic Resonance Imaging methods
- Abstract
We report a new type of SSFP imaging sequences for acquiring higher-order echoes. Spins excited during a cycle have, in a sense, a phase memory such that they can be refocused several cycles down the line, and since the spins are pulsed under a steady-state condition, the resulting echoes have very complicated T1 and T2 dependencies. A steady-state equation, which describes the T1 and T2 dependencies for the higher-order echoes, is presented, and the intensity of each echo is calculated and compared with the experimental results. Although the signal intensity of the higher-order echoes are weaker than the FID or the CE-FAST echo, these echoes may be used to obtain images with different contrast dependencies previously unobtainable with either of the two signals.
- Published
- 1991
- Full Text
- View/download PDF
49. Hypoxia-induced fatal aircraft accident revealed by voice analysis.
- Author
-
Saito I, Fujiwara O, Utsuki N, Mizumoto C, and Arimori T
- Subjects
- Adult, Altitude, Humans, Hypoxia diagnosis, Male, Oxygen Consumption, Reaction Time, Time Factors, Accidents, Aviation, Hypoxia complications, Voice
- Abstract
The voice communication was the only clue of the fatal F-104J accident encountered during high-altitude intercept procedures, and it was analysed to prove the presence of hypoxia as a causal factor. A simulated low-pressure chamber flight was undertaken, and the subject's voice, saying the same words as the pilot, was analyzed in the same way. Comparison of these two voices revealed a similarity in characteristic changes of the sound spectrum and time course. The blurred formation of formant, fundamental, and harmonic frequencies, as well as the obscured gap in pre-vocal cord opening time (VOT) of the sound spectrogram, were thought to be the effects of hypoxia. Lowered fundamental frequency of the pilot's voice, even at the stressful period of attack, has strongly suggested decreased vigilance due to hypoxia. Through these findings, it was concluded that the cause of the accident was probably hypoxia in the pilot.
- Published
- 1980
50. Seroepidemiology of human syncytial virus: antibody prevalence in the Pacific.
- Author
-
Loh PC, Matsuura F, and Mizumoto C
- Subjects
- Female, Fluorescent Antibody Technique, Hawaii, Humans, Independent State of Samoa, Male, Neutralization Tests, New Caledonia, Pacific Islands, Polynesia, Vanuatu, Antibodies, Viral analysis, Retroviridae immunology, Spumavirus immunology
- Abstract
A seroepidemiological survey of the human syncytial (foamy) virus was done by means of an indirect immunofluorescence test on 1,717 sera from nine different Pacific island territories. The specificity of the reaction was verified by neutralization tests. The study indicated that the virus is ubiquitous in this part of the world, with no region being entirely free of antibody. The antibody prevalence ranged from a low of 1.2% in Ponape to a high of 15.6% in the Cook Islands. The average prevalence for the nine insular communities was 6.9%.
- Published
- 1980
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.